Sign in

    Ben Burnett

    Managing Director and Equity Analyst at Stifel

    Ben Burnett is a Managing Director and Equity Analyst at Stifel specialized in biotechnology, with a focus on covering innovative companies such as Iovance, Cabaletta, Arcellx, Revolution Medicines, Fate Therapeutics, CRISPR Therapeutics, and Disc Medicine. He is known for his in-depth sector coverage and for leading investor engagements with major firms like IDEAYA Biosciences, reflecting a prominent reputation within the life sciences investment community. Burnett joined Stifel as a senior analyst following prior research experience, and he regularly moderates high-profile industry events and forums featuring key biotechnology executives. Holding a Ph.D. and recognized for his leadership in the biotech equity research space, Burnett maintains active FINRA registration and required securities licenses, demonstrating both subject-matter expertise and regulatory compliance.

    Ben Burnett's questions to Allogene Therapeutics (ALLO) leadership

    Ben Burnett's questions to Allogene Therapeutics (ALLO) leadership • Q4 2024

    Question

    Carolina Ibanez-Ventoso on for Ben Burnett asked for the specific timing of the MRD conversion measurement for the mid-2025 interim analysis of the cema-cel ALPHA3 trial.

    Answer

    EVP of R&D and CMO Dr. Zachary Roberts responded that the company has not disclosed the exact timing of the MRD sample draw. He also noted that the lymphodepletion decision will be based on an assessment of multiple elements, not just the MRD conversion data.

    Ask Fintool Equity Research AI

    Ben Burnett's questions to FATE THERAPEUTICS (FATE) leadership

    Ben Burnett's questions to FATE THERAPEUTICS (FATE) leadership • Q1 2024

    Question

    On behalf of Ben Burnett from Stifel, an analyst asked what the ex-vivo data from the SLE patient sample implies about the necessary FT819 dose and expansion required to achieve deep B-cell depletion in vivo.

    Answer

    Dr. Bob Valamehr, Chief Research and Development Officer, explained that the data showed effective B-cell elimination at a 2:1 effector-to-target ratio. Given an estimated disease burden of 100-300 million B-cells in an SLE patient, the current dose of 360 million cells is well-positioned to match the effective dose seen in vitro, providing confidence in its potential for in-vivo efficacy.

    Ask Fintool Equity Research AI

    Ben Burnett's questions to IDEAYA Biosciences (IDYA) leadership

    Ben Burnett's questions to IDEAYA Biosciences (IDYA) leadership • Q1 2022

    Question

    Ben Burnett inquired about the expected duration of SDMA and SAM level reduction required to observe a clinical response and asked if the company plans to continue dose escalation until an MTD is reached.

    Answer

    Chief Scientific Officer Michael White explained that the time to response could vary by indication but requires continuous, strong target suppression. CEO & President Yujiro Hata added that they believe they are in the efficacious range at Cohort 6 and could start expansion there while continuing to escalate in parallel to formally define the MTD.

    Ask Fintool Equity Research AI